Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,439,232
  • Shares Outstanding, K 1,244,992
  • Annual Sales, $ 27,116 M
  • Annual Income, $ 5,665 M
  • EBIT $ 2,558 M
  • EBITDA $ 5,251 M
  • 60-Month Beta 0.17
  • Price/Sales 4.08
  • Price/Cash Flow 9.93
  • Price/Book 6.08

Options Overview Details

View History
  • Implied Volatility 29.06% ( -2.20%)
  • Historical Volatility 14.30%
  • IV Percentile 92%
  • IV Rank 71.97%
  • IV High 33.98% on 08/05/24
  • IV Low 16.44% on 12/05/23
  • Put/Call Vol Ratio 0.55
  • Today's Volume 5,777
  • Volume Avg (30-Day) 6,764
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 246,949
  • Open Int (30-Day) 248,704

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.58
  • Number of Estimates 12
  • High Estimate 1.92
  • Low Estimate 1.41
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -31.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.10 +7.71%
on 10/02/24
89.74 -0.26%
on 10/25/24
+5.57 (+6.64%)
since 10/01/24
3-Month
72.43 +23.58%
on 08/12/24
89.74 -0.26%
on 10/25/24
+13.02 (+17.02%)
since 08/01/24
52-Week
62.07 +44.21%
on 05/31/24
89.74 -0.26%
on 10/25/24
+9.32 (+11.62%)
since 11/01/23

Most Recent Stories

More News
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 101.88 (-0.43%)
NVS : 109.35 (+0.88%)
GILD : 89.51 (+0.78%)
3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and...

UHS : 205.26 (+0.46%)
LLY : 818.93 (-1.30%)
GILD : 89.51 (+0.78%)
ISRG : 506.34 (+0.50%)
AMGN : 319.22 (-0.29%)
DVA : 141.59 (+1.27%)
Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

XLV : 147.74 (+0.59%)
$SPX : 5,728.80 (+0.41%)
GILD : 89.51 (+0.78%)
Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed...

MRK : 101.88 (-0.43%)
ALNY : 273.91 (+2.75%)
GILD : 89.51 (+0.78%)
GSK : 36.88 (+0.33%)
Covered Call Screener Results For October 17th

Covered calls are a great strategy to add to any portfolio and can offer enhanced yield from stock holdings, in some cases, that can be a significant increase.

SBUX : 98.87 (+1.20%)
NEM : 45.26 (-0.40%)
XOM : 114.95 (-1.57%)
GILD : 89.51 (+0.78%)
MMM : 127.22 (-0.97%)
PFE : 28.09 (-0.74%)
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention...

GILD : 89.51 (+0.78%)
GSK : 36.88 (+0.33%)
PFE : 28.09 (-0.74%)
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final overall survival...

AZN : 71.42 (+0.38%)
MRK : 101.88 (-0.43%)
GILD : 89.51 (+0.78%)
PFE : 28.09 (-0.74%)
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.

IBB : 142.78 (+1.77%)
GILD : 89.51 (+0.78%)
XBI : 99.27 (+2.31%)
3 Dirt Cheap Stocks to Buy Right Now

Bargain hunters should love these great stocks.

CRSP : 50.76 (+9.42%)
GILD : 89.51 (+0.78%)
PFE : 28.09 (-0.74%)
Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

$DOWI : 42,052.19 (+0.69%)
GILD : 89.51 (+0.78%)
BIIB : 173.79 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 91.37
2nd Resistance Point 90.47
1st Resistance Point 89.99
Last Price 89.51
1st Support Level 88.61
2nd Support Level 87.71
3rd Support Level 87.23

See More

52-Week High 89.74
Last Price 89.51
Fibonacci 61.8% 79.17
Fibonacci 50% 75.90
Fibonacci 38.2% 72.64
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar